Sudler's Metropoulos to head Euro RSCG Life, Pantello named chairman

Euro RSCG Life Worldwide reshuffled its top management, with Jim Metropoulos signing on as CEO of the Havas healthcare network from WPP’s Sudler & Hennessey, where he was co-president. He reports to David Jones, global CEO of Euro RSCG Worldwide. Metropoulos succeeds Ron Pantello, who becomes chairman of the network, a new position. Pantello will stay on full-time until the end of the year, managing the transition, and will then drop down to part-time, working as a strategic consultant and mentor to the new management team. The network also named Doug Burcin and Ed Stapor, the heads of its two largest US units, co-CEOs for North America, new posts reporting to Metropoulos. Burcin is president of Euro RSCG Life Metamax, which handles key Sanofi-Aventis accounts, and Stapor heads Euro RSCG Life Chelsea. They join Michel Nakache, CEO for Euro RSCG Life Europe/Asia, who also reports to Metropoulos. “It puts into place a nice management team for the future,” said Pantello. “These are all guys in their 40s. It’s a nice succession plan to continue driving this business forward.” Pantello, an LM&P co-founder who has been with the company for 26 years, has served as CEO of the group since 2002. He presided over a consolidation of the sprawling agency network and engineered its realignment under the “Power of One” model, featuring a single profit-and-loss statement and centralized, media-neutral offering. He is also chairman emeritus of the Medical Advertising Hall of Fame.
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.